The NASA Discovery mission EPOXI, utilizing the Deep Impact flyby spacecraft, comprises two phases: EPOCh (Extrasolar Planet Observation and Characterization) and DIXI (Deep Impact eXtended Investigation). With EPOCh, we use the 30-cm high resolution visible imager to obtain ultraprecise photometric light curves of known transiting planet systems. We will analyze these data for evidence of additional planets, via transit timing variations or transits; for planetary moons or rings; for detection of secondary eclipses and the constraint of geometric planetary albedos; and for refinement of the system parameters. Over a period of four months, EPOCh observed four known transiting planet systems, with each system observed continuously for several weeks. Here we present an overview of EPOCh, including the spacecraft and science goals, and preliminary photometry results.

EPOXI (EPOCh + DIXI) is a NASA Discovery Program Mission of Opportunity using the Deep Impact flyby spacecraft. The EPOCh (Extrasolar Planet Observation and Characterization) Science Investigation will gather photometric time series of known transiting exoplanet systems from January through August 2008. Here we describe the steps in the photometric extraction of the time series and present preliminary results of the first four EPOCh targets.

This study developed a method for measuring subjective costs and benefits of psychiatric treatments. Forty-one patients rated the relative bothersomeness of symptoms of schizophrenia and side effects of neuroleptics. Thirty-four psychiatrists made parallel ratings from the perspective of the average patient (individual utility) and of the patient's family and society (institutional utility). Psychiatrists predicted patients' ratings moderately well, but misjudged the bothersomeness to patients of 24% of side effects and 20% of symptoms. When considering the patient's perspective, both schizophrenic patients and psychiatrists rated symptoms as no more bothersome than side effects. However, psychiatrists saw side effects as significantly less bothersome than symptoms when considering costs to society. The subjective utility of neuroleptic medications for schizophrenia is most justifiable from an institutional perspective.